+Vote!
Contract Pharma Breaking News (Free subscription) | 30/09/2008
MedImmune has licensed its reverse genetics technology to Biken, The Research Foundation for Microbial Diseases of Osaka University in Japan, for the development of new vaccine strains to produce non-live human influenza vaccines. Reverse genetics is a method that uses segments of DNA to generate viruses such as influenza. This method helps protect manufacturers from exposure to potentially highly...
+Vote!
Virginia Biotechnology Association (Free subscription) | 26/09/2008
The 2008 Mid-Atlantic Bio committee announced that David M. Mott will address the conference as a plenary session speaker. Mr. Mott is a top biotechnology executive who led industry giant MedImmune to the largest biotech acquisition to date when it...
+Vote!
The Baltimore Business Journal (Free subscription) | 19/09/2008
David Mott, former chief executive of MedImmune Inc., has joined New Enterprise Associates Inc. as general partner at the venture capital firm.
+Vote!
Fiercebiotech (Free subscription) | 18/09/2008
MedImmune's ex-CEO, David Mott, is starting a new career as a venture capitalist. He's been named a general partner at New Enterprise Associates, a busy investor in the biotech field. Mott says he will focus on biotechnology and specialty pharma. Mott left MedImmune last July , a year after it was bought out by AstraZeneca for $15.6 billion. And the acquisition didn't leave Mott hurting for money....
+Vote!
PharmaGossip (Free subscription) | 18/09/2008
US venture capital firm New Enterprise Associates has appointed David M Mott as general partner. Mott will focus on biotechnology and specialty pharmaceutical investing within NEA's East Coast healthcare practice. Prior to joining NEA, Mott was president and CEO of MedImmune, subsidiary of AstraZeneca, and executive vice president of AstraZeneca. He joined MedImmune in 1992 and also founded the company's...
+Vote!
Fiercebiotech (Free subscription) | 15/09/2008
MedImmune says it has voluntarily suspended three mid-stage trials for an experimental asthma medication. The FDA has also placed a clinical hold MEDI-528. The news also marks a setback for Genaera, which is collaborating with MedImmune on new asthma therapies. Report
+Vote!
Contract Pharma Breaking News (Free subscription) | 12/09/2008
MedImmune, the global biologics unit of AstraZeneca, and SBI Biotech Co. , Ltd, have entered into a licensing and collaboration agreement to develop and commercialize SBI Biotech's anti-ILT7 protein for the potential treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases. MedImmune will have global rights to any resulting product candidates and will be responsible for preclinical...
+Vote!
IPBiz (Free subscription) | 05/09/2008
In another post-MedImmune case on DJs, the CAFC said: Defendant-Appellant Apotex, Inc. (Apotex) appeals the order of the United States District Court for the District of New Jersey dismissing its declaratory judgment action for noninfringement against Plaintiffs-Appellees Janssen Pharmaceutica, N.V. and Janssen, L.P. (collectively Janssen). We affirm. Apotex loses. This is not a bad case to review...
+Vote!
IPBiz (Free subscription) | 03/09/2008
MarketWatch notes: A free webinar on the impact of the eBay, KSR, MedImmune, Seagate and Translogic cases will be presented on 25 Sept. Benefits are stated to include learning: -- How much harder it is for patent holders to obtain injunctions against infringing products since eBay. -- What patent licensing and enforcement conduct will trigger declaratory judgment jurisdiction after MedImmune. -- What...
+Vote!
The Tom Peters Weblog (Free subscription) | 28/08/2008
Signs of summer's imminent ending include this first of the fall season's events for Tom. He is speaking today in...
+Vote!
Seeking Alpha (Free subscription) | 19/08/2008
Mike Huckman submits: Ads for flu vaccines have traditionally been confined to public service announcements (PSAs), health and media alerts. So, that's why I was surprised to see this colorful full-page ad in The New York Times last weekend for FluMist from AstraZeneca (AZN)/MedImmune. Complete Story »
+Vote!
IPBiz (Free subscription) | 16/08/2008
The fate of the TSM test in obviousness, post KSR, has been discussed. Note also the fate of "reasonable apprehension", post MedImmune, is also being discussed. In Prasco v. Medicis, the CAFC gives a thorough discussion, post MedImmune, of DJ jurisdiction. In the case, Prasco lost, with the CAFC noting: Prasco has failed to establish a case or controversy under Article III. **The CAFC noted of MedImmune,...
+Vote!
Medical News Today (Free subscription) | 13/08/2008
MedImmune announced that it has initiated enrollment in a Phase 2A trial with an investigational human monoclonal antibody (MAb) targeting interferon-alpha in patients with systemic lupus erythematosus (SLE or lupus).
+Vote!
Medical,Health News and Articles (Free subscription) | 11/08/2008
With the approval, the U.S. FDA has targeted three new strains of ‘flu. Six pharma firms will benefit from the approval, including GlaxoSmithKline, MedImmune (part of AstraZeneca), and Sanofi Pasteur. The FDA’s modification of the strains in the 2008/09 ‘flu vaccine list is significant, as including three strains rather than updating one or two strains [...]
+Vote!
Medical News Today (Free subscription) | 10/08/2008
With the approval, the U.S. FDA has targeted three new strains of 'flu. Six pharma firms will benefit from the approval, including GlaxoSmithKline, MedImmune (part of AstraZeneca), and Sanofi Pasteur. The FDA's modification of the strains in the 2008/09 'flu vaccine list is significant, as including three strains rather than updating one or two strains has been described as an "unusual occurrence"....
